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Alpha-one antitrypsin (AAT) deficiency is a genetic disease affecting the lungs due to 
inadequate anti-protease activity in the pulmonary interstitium. On-going human trials use intra-
muscular delivery of adeno-associated virus (rAAV1), allowing expressing myofibers to secrete 
normal (M)AAT protein. In the Phase IIa trial, patients in the highest dose cohort (6x1012vg/kg) 
were given 100 intra-muscular (IM) injections of undiluted vector, with serum AAT levels still 
substantially below target levels. Previous work has shown that delivering rAAV vector to the 
musculature via limb perfusion leads to widespread gene expression in myofibers. We 
hypothesize that widespread delivery would result in an overall increase in serum AAT levels 
with the same dose of AAV gene therapy vector and allow for increased volume and thereby 
dose of vector. In macaques, similar serum myc-tagged rhAAT was produced using regional 
venous infusion when compared to direct IM delivery at the same total vg dose with either 
rAAV1 or rAAV8, while not being limited to a small volume as with IM injection. These data 
prove the concept that a 30-fold expanded volume of rAAV-AAT could be delivered to myofibers 
using limb perfusion without loss of potency on a per vg basis, thereby enabling potential 
achievement of therapeutic AAT levels in patients. This will allow us to proceed to a phase IIb 
clinical trial in AAT patients employing venous limb perfusion.  
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